Phase II Study of MEDI4736 monotherapy or in combinations with Tremelimumab in Metastatic Pancreatic Ductal Carcinoma

Trial Identifier: D4198C00001
Sponsor: AstraZeneca
NCTID:: NCT02558894
Start Date: November 2015
Primary Completion Date: June 2017
Study Completion Date: June 2017
Condition: Cancer - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English translation
Dutch translation
Korean translation

Trial Locations

Country Location
Canada, BC Vancouver, BC, Canada, V5Z 4E6
Canada, ON Oshawa, ON, Canada, L1G 2B9
Canada, ON Ottawa, ON, Canada, K1H 8L6
Canada, ON Toronto, ON, Canada, M5G 2M9
Canada, ON Toronto, ON, Canada, M4N 3M5
Canada, QC Montreal, QC, Canada, H4A 3T2
Germany Berlin, Germany, 13353
Germany Friedrichshafen, Germany, 88045
Germany München, Germany, 81377
Germany Tuebingen, Germany, 72076
Germany Würzburg, Germany, 97080
Netherlands AMSTERDAM, Netherlands, 1105 AZ
Netherlands Groningen, Netherlands, 9713 GZ
Netherlands Nijmegen, Netherlands, 6525 GA
South Korea Seongnam-si, South Korea, 463-707
South Korea Seoul, South Korea, 03722
South Korea Seoul, South Korea, 06591
South Korea Seoul, South Korea, 135-710
South Korea Seoul, South Korea, 03080
Spain Barcelona, Spain, 08025
Spain Barcelona, Spain, 08035
Spain Madrid, Spain, 28041
Spain Madrid, Spain, 28034
United States of America, CA Los Angeles, CA, United States of America, 90048
United States of America, CA Stanford, CA, United States of America, 94305
United States of America, FL Tampa, FL, United States of America, 33612
United States of America, MI Detroit, MI, United States of America, 48201
United States of America, NY New York, NY, United States of America, 10065
United States of America, NY Rochester, NY, United States of America, 14642
United States of America, PA Pittsburgh, PA, United States of America, 15232